Form 4 for BIIB Biogen
Accepted 2023-09-06 00:00:00 ET · period of report 2023-09-01 · accession 0001127602-23-023825 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-09-06 | 2023-09-01 | BIIB | MCDONNELL MICHAEL R | EVP, CFO | M - OptEx | $0.00 | +5,285 | 14.1K | +60% | $0 |
| DM | 2023-09-06 | 2023-09-01 | BIIB | MCDONNELL MICHAEL R | EVP, CFO | F - Tax | $267.17 | -2,704 | 11.5K | -19% | -$722.4K |
| D | 2023-09-06 | 2023-09-01 | BIIB | MCDONNELL MICHAEL R | EVP, CFO | J - Other | $0.00 | -2,763 | 0 | -100% | $0 |
| DM | 2023-09-06 | 2023-09-01 | BIIB | MCDONNELL MICHAEL R | EVP, CFO | M - OptEx | $0.00 | -5,285 | 2,763 | -66% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-01 | M | A | 2,682 | $0.00 | 12,829 | D | — | — | |
| 2 | Common | Common Stock | 2023-09-01 | F | D | 1,332 | $267.17 | 12,728 | D | — | — | |
| 3 | Common | Common Stock | 2023-09-01 | M | A | 2,603 | $0.00 | 14,060 | D | — | — | |
| 4 | Common | Common Stock | 2023-09-01 | F | D | 1,372 | $267.17 | 11,457 | D | — | — | |
| 5 | Derivative | Restricted Stock Unit | 2023-09-01 | J | D | 2,763 | $0.00 | 0 | D | $0.00 · — to 2023-09-01 | 2,763 Common Stock | (F2) The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average closing stock price for the 30 calendar days following and including the grant date and 30 calendar days prior to and including such vesting date]). |
| 6 | Derivative | Restricted Stock Unit | 2023-09-01 | M | D | 2,682 | $0.00 | 0 | D | $0.00 · — to 2023-09-01 | 2,682 Common Stock | (F1) The restricted stock units vested in three (3) equal annual installments commencing one year after the grant date of 09/01/2020. |
| 7 | Derivative | Restricted Stock Unit | 2023-09-01 | M | D | 2,603 | $0.00 | 2,763 | D | $0.00 · — to 2023-09-01 | 2,603 Common Stock | (F2) The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average closing stock price for the 30 calendar days following and including the grant date and 30 calendar days prior to and including such vesting date]). |